Hepion raises $700K in private placement
Hepion Pharmaceuticals, Inc. entered into securities purchase agreements with accredited investors for a private placement of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Hepion Pharmaceuticals, Inc. entered into securities purchase agreements with accredited investors for a private placement of common stock. The company agreed to sell an aggregate of 17,500,000 shares of common stock at an offering price of $0.04 per share, for gross proceeds of $700,000.
The transaction closed on April 21, 2026. The shares were issued in an unregistered offering relying on exemptions under Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D, meaning they cannot be freely resold in the United States without registration or a valid exemption.
8-K Event Classification
3 items: 1.01, 3.02, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 3.02
Unregistered Sales of Equity Securities
Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Shares issued: 17,500,000 shares
Offering price: $0.04 per share
Gross proceeds: $700,000
+2 more
5 metrics
Shares issued
17,500,000 shares
Aggregate common stock sold in private placement
Offering price
$0.04 per share
Price of common stock in the private placement
Gross proceeds
$700,000
Total proceeds from the April 21, 2026 offering
Securities Act exemption
Section 4(a)(2) and/or Rule 506(b)
Exemptions relied upon for unregistered sale
Closing date
April 21, 2026
Date the private placement closed
Key Terms
securities purchase agreements, private placement offering, accredited investors, Section 4(a)(2), +2 more
6 terms
securities purchase agreements financial
"entered into securities purchase agreements (the “Agreements”) with certain accredited investors"
A securities purchase agreement is a legal contract that spells out the terms when a company sells stocks, bonds, or other investment instruments to buyers. It lays out price, how many securities change hands, any promises or protections for each side, and when the sale is completed—like a detailed sales contract for investments. Investors care because it determines ownership stakes, potential dilution, rights attached to the securities, and conditions that affect the company’s future value.
private placement offering financial
"to sell and issue to the Investors in a private placement offering (the “Offering”)"
A private placement offering is when a company sells its stock or bonds directly to a small group of investors instead of offering them to the general public. This allows the company to raise money quickly and privately, often for specific projects or needs, without going through a public stock exchange.
accredited investors financial
"entered into securities purchase agreements (the “Agreements”) with certain accredited investors"
Accredited investors are individuals or entities considered to have enough financial knowledge and resources to understand and handle more complex and risky investments. They are often allowed to participate in private investment opportunities that are not available to the general public, similar to how experienced players might access exclusive clubs or events. This status helps ensure that investors can manage potential risks and rewards appropriately.
Section 4(a)(2) regulatory
"offered in reliance upon the exemption from the registration requirement ... pursuant to Section 4(a)(2) thereof"
Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.
Rule 506(b) of Regulation D regulatory
"and/or Rule 506(b) of Regulation D promulgated thereunder"
Rule 506(b) of Regulation D is a set of rules that allows companies to raise money from investors without having to register with the government, as long as they follow certain guidelines. It lets companies offer securities to a limited number of investors, often trusted or experienced ones, making it easier and quicker to raise funds compared to traditional methods. This rule matters to investors because it provides access to private investment opportunities that are generally less regulated but still require careful consideration.
unregistered sale of equity securities regulatory
"Item 3.02 Unregistered Sale of Equity Securities."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What financing transaction did Hepion Pharmaceuticals (HEPA) disclose in this 8-K?
Hepion Pharmaceuticals disclosed a private placement of common stock. The company entered securities purchase agreements to sell 17,500,000 shares at $0.04 per share, generating $700,000 in gross proceeds from accredited investors in a single closing on April 21, 2026.
Was the Hepion Pharmaceuticals (HEPA) stock offering registered with the SEC?
The stock offering was not registered with the SEC. Hepion relied on exemptions from registration under Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D, so the issued shares cannot be offered or sold publicly without registration or another applicable exemption.
Who participated in the Hepion Pharmaceuticals (HEPA) private placement?
The private placement involved certain accredited investors as counterparties. Hepion entered into securities purchase agreements with these investors, who purchased an aggregate of 17,500,000 shares of common stock at $0.04 per share in a single closing on April 21, 2026.
What type of agreement did Hepion Pharmaceuticals (HEPA) use for this financing?
Hepion used securities purchase agreements for the financing. These agreements included customary representations, warranties, conditions to closing, indemnification obligations, other obligations of the parties, and termination provisions for the private placement of 17,500,000 common shares at $0.04 per share.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates